Commonwealth Equity Services LLC Sells 92 Shares of Repligen Co. (NASDAQ:RGEN)

Commonwealth Equity Services LLC cut its holdings in Repligen Co. (NASDAQ:RGEN) by 1.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,228 shares of the biotechnology company’s stock after selling 92 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Repligen were worth $896,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Conestoga Capital Advisors LLC grew its stake in shares of Repligen by 0.7% in the 4th quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock worth $136,395,000 after buying an additional 6,872 shares in the last quarter. DF Dent & Co. Inc. grew its position in Repligen by 31.0% in the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock worth $87,852,000 after acquiring an additional 139,615 shares in the last quarter. New York State Common Retirement Fund increased its stake in Repligen by 2.5% during the fourth quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company’s stock worth $83,693,000 after acquiring an additional 14,398 shares during the last quarter. Stephens Investment Management Group LLC raised its position in Repligen by 7.4% during the fourth quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company’s stock valued at $77,267,000 after purchasing an additional 37,057 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Repligen by 79.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company’s stock valued at $65,395,000 after purchasing an additional 203,011 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. boosted their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Evercore ISI started coverage on shares of Repligen in a research note on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $180.00 target price on shares of Repligen in a report on Friday, February 21st. Royal Bank of Canada upped their price target on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. Finally, StockNews.com downgraded shares of Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $178.64.

Insider Buying and Selling

In other Repligen news, Director Margaret Pax purchased 250 shares of Repligen stock in a transaction dated Monday, March 17th. The stock was acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now owns 1,043 shares in the company, valued at $157,169.67. This trade represents a 31.53 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.20% of the stock is owned by insiders.

Repligen Stock Performance

Repligen stock opened at $128.50 on Wednesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The company has a market capitalization of $7.22 billion, a PE ratio of -251.96, a P/E/G ratio of 4.54 and a beta of 0.95. The company has a 50 day moving average price of $152.75 and a 200-day moving average price of $148.00. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $182.52.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. As a group, equities analysts forecast that Repligen Co. will post 1.72 earnings per share for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.